IPAR

Publicly Available Assessment Report for a Veterinary Medicinal Product

Sporimune 50 mg/ml oral solution for cats and dogs

"This product was originally authorised under an EU procedure prior to 1st January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

PRODUCT SUMMARY

EU Procedure number	IE/V/0302/001/DC
Name, strength and pharmaceutical form	Sporimune 50 mg/ml Oral Solution for Dogs and Cats
Active substance	Ciclosporin
Applicant	Le Vet Beheer BV. Wilgenweg 7 3421 TV Oudewater The Netherlands
Legal basis of application	Generic application in accordance with Article 13 of Directive 2001/82/EC as amended.
Date of completion of the decentralised procedure	29th May 2013
Target species	Dogs, cats
Indications for use	Treatment of chronic manifestations of atopic dermatitis in dogs. Symptomatic treatment of chronic allergic dermatitis in cats.
ATCvet code	QL04AD01
Concerned Member States	AT, BE, CY, CZ, DE, DK, EE, EL, ES, FI, FR, HR, HU, IE, IS, IT, LT, LU, LV, NL, NO, PL, PT, RO, SE, SI, SK, UK

PUBLIC ASSESSMENT REPORT

The public assessment report reflects the scientific conclusion reached by the HPRA at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in Article 25.4 of EC Directive 2001/82/EC as amended by Directive 2004/28/EC for veterinary medicinal products. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the product for marketing in Ireland.

The Summary of Product Characteristics (SPC) for this product is available on the HPRA's website.

I. SCIENTIFIC OVERVIEW

Sporimune 50 mg/ml oral solution for dogs and cats contains ciclosporin as active pharmaceutical ingredient. This application was submitted in accordance with Article 13 of Directive 2001/82/EC, as amended (a generic application). The reference product cited in that application was Atopica 50 mg soft capsules (Novartis Sante Animale) as first authorised in France on 12/08/2002.

Sporimune 50 mg/ml oral solution for first authorised for use in dogs (approved in 2013). In 2015, a variation application was submitted in order to add cats as target species.The reference product cited in the variation was Atopica 100mg/ml oral solution for cats (Novartis Animal Health UK Ltd.) as first authorised in the UK on 7/10/2011.Atopica 100mg/ml oral solution for cats was authorised as an extension to Atopica 10mg, 25mg, 100mg soft capsules for dogs.It can be accepted that Atopica 100mg/ml Oral Solution is part of the same global marketing authorisation as Atopica 10mg, 25mg, 100mg soft capsules for dogs.

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species. The occurrence of adverse reactions is uncommon and information on possible adverse reactions is indicated in the SPC.

The product is safe for the user and for the environment, when used as recommended.Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Qualitative and Quantitative Particulars

The product contains 50 mg/ml ciclosporinand the excipients ethanol anhydrous, tocopherol acetate, diethylene glycol monoethyl ether, oleyl macrogolglycerol hydroxystearate and macrogolglycerol hydroxystearate.
The product is presented in type III glass bottles closed with a polypropylene (PP) stopper with a Teflon inlay.One bottle and a dispenser set (consisting of a child resistant HDPE screw cap and a 1 ml PP dosing syringe for cats and a 5 ml PP dosing syringe for dogs) packed in a cardboard box
On first use of the product the polypropylene stopper should be replaced with a second screw cap stopper which contains an adaptor to aid administration of the product using a syringe.The second screw cap stopper and syringes are supplied with the bottle and the information leaflet in individual cardboard cartons.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.
Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is ciclosporin an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.
The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

D. Control on Intermediate Products

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.
Satisfactory validation data for the analytical methods have been provided.
Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability

The stability of the active substance has been established in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.
Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

G. Other Information

Not applicable.

III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pre-clinical and clinical tests are not required.

Warnings and precautions as listed on the product literature are in line with those of the reference product and are adequate to ensure safety of the product to users and the environment.

III. A Safety Testing Pharmacological Studies

The applicant provided the results of two proprietary *in vivo* comparative bioavailability studies conducted to investigate the bioequivalence of the candidate formulation with the reference product when administered to dogs and cats.

Based upon the results of this study, it was accepted that the product was bioequivalent with the reference product for both pivotal pharmacokinetic parameters AUC_t and C_{max}.

Toxicological Studies

This application has been submitted in accordance with Article 13 of Directive 2001/82/EC, as amended. Article 13.1 states that 'the applicant shall not be required to provide the results of the safety and residue tests or of the pre-clinical and clinical trials if he can demonstrate that the medicinal product is a generic of a reference product.

Therefore, no toxicological studies were required.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline.

The active pharmaceutical ingredient of the candidate formulation (ciclosporin) has been used in human medicine for a number of years with the highest dose rates used in patients undergoing organ/tissue transplantation. The exposure scenarios presented by the applicant were accepted as being representative of reasonable worst case scenarios. The applicant provided the results of ocular and dermal irritancy studies and it was concluded from the results of these studies that the candidate formulation is neither an ocular nor a dermal irritant.

Based upon the data presented, it was concluded that the candidate formulation is unlikely to present an unacceptable risk for the user when handled, stored, used and disposed of in accordance with the proposed SPC.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment Phase I

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment is required. The assessment concluded that the product is intended solely for use in non-food producing animals and the assessment may end in Phase I.

Conclusion

Based on the data provided, the ERA can stop at Phase I. The product is not expected to pose an unacceptable risk for the environment when used according to the SPC.

III. B Residues Documentation

No data presented.

Given the intended target species for this application (a veterinary medicinal product to be administered solely to dogs and cats), absence of residue data can be accepted.

IV. CLINICAL ASSESSMENT

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

IV.APre-Clinical Studies Pharmacology

This application has been submitted in accordance with Article 13 of Directive 2001/82/EC, as amended. Article 13.1 states that 'the applicant shall not be required to provide the results of the safety and residue tests or of the pre-clinical and clinical trials if he can demonstrate that the medicinal product is a generic of a reference product. Therefore, no pre-clinical studies were required.

Tolerance in the Target Species of Animals

The applicant presented the results of a target animal tolerance study investigating tolerance of the candidate formulation in the dog following oral administration for a period of 28 days at up to five times the recommended therapeutic dose. Local and systemic tolerance to the candidate formulation was considered acceptable.

For the cat, no specific target animal tolerance study was conducted with the candidate formulation. However, it is accepted that the substance of primary concern with respect to systemic tolerance is the active substance, ciclosporin. Given that bioequivalence with the reference product is accepted, it follows that the risk to the cats arising from the use of this product will be similar to the risks associated with the reference product. Further, in the bioequivalence study, the test item was generally well tolerated. Vomiting was observed in one animal approximately 8 hours after dosing with the test product.This is a known potential adverse effect of both the reference and test item.

It was accepted that the candidate formulation is unlikely to present an unacceptable risk to the target species.

IV.B Clinical Studies Laboratory Trials Field Trials

No clinical trial data was presented. Given that the applicant provided the results of an *in vivo* comparative bioavailability study to demonstrate bioequivalence of the candidate formulation with the reference product, the absence of clinical trial data was accepted.

V. OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the benefit/risk profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

VI. POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the HPRA website.

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Changes:

Safety/Efficacy Changes

Summary of change **(Application number)**	**Approval date**
Addition of target species - cats	22/4/2016
(**IE/V/0302/001/II/002**)	